NexCAR19 (Talikabtagene Autoleucel) in Relapsed/Refractory B-Cell Malignancies (NexCAR19)

The NexCAR19 study is a national, open-label, multicenter Phase 2-3 clinical trial designed to evaluate the efficacy and safety of the anti-CD19 chimeric antigen receptor (CAR) T-cell product, Talikabtagene Autoleucel, in patients with relapsed/refractory B-cell malignancies, including B-cell Acute Lymphoblastic Leukemia (B-ALL) and Non-Hodgkin Lymphoma. The study is supported by the Presidency of Turkish Health Institutes (TÜSEB) and will be conducted at four centers. This therapy is based on collecting the patient's own T cells, genetically modifying them in a laboratory to recognize the CD

Trial Details

NCT ID
NCT07502118
Phase
PHASE2 / PHASE3
Sponsor
Health Institutes of Turkey
Status
RECRUITING
Cancer Type
Diffuse Large B-Cell (DLBCL) Lymphoma
Interventions
  • Talikabtagene Autoleucel
Locations (sample)
  • Ankara, Turkey (Türkiye)|39.91987,32.85427
  • Ankara, Turkey (Türkiye)|39.91987,32.85427
  • Ankara, Turkey (Türkiye)|39.91987,32.85427
  • Ankara, Turkey (Türkiye)|39.91987,32.85427

Key Eligibility Criteria

  • All participants must meet Inclusion Criteria 1-13.
  • Additionally:
  • High-grade lymphoma subjects must meet Criteria 14-18.
  • Other B-cell lymphoma subjects must meet Criteria 19-24.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Diffuse Large B-Cell (DLBCL) Lymphoma Trials on Trialify →